Structural Modification of Noscapine via Photoredox/Nickel Dual Catalysis for the Discovery of S-Phase Arresting Agents.

Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
08 Feb 2024
Historique:
received: 16 10 2023
revised: 28 12 2023
accepted: 02 01 2024
pmc-release: 08 02 2025
medline: 14 2 2024
pubmed: 14 2 2024
entrez: 14 2 2024
Statut: epublish

Résumé

Herein, we disclose a powerful strategy for the functionalization of the antitumor natural alkaloid noscapine by utilizing photoredox/nickel dual-catalytic coupling technology. A small collection of 37 new noscapinoids with diverse (hetero)alkyl and (hetero)cycloalkyl groups and enhanced sp

Identifiants

DOI: 10.1021/acsmedchemlett.3c00462 PMID: 38352836 PMC: PMC10860181
pubmed: 38352836
doi: 10.1021/acsmedchemlett.3c00462
pmc: PMC10860181
doi:

Types de publication

Journal Article

Langues

eng

Pagination

230-238

Informations de copyright

© 2024 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Auteurs

Defeng Li (D)

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China.

Chuanxu Liu (C)

Department of Lymphoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China.

Tingyu Guo (T)

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China.

Jiajie Zhu (J)

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China.

Jiaqi Guo (J)

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China.

Ting Luo (T)

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China.

Yuhuan Liu (Y)

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China.

Wenhao Shen (W)

Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, P. R. China.

Biao Jiang (B)

Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, P. R. China.

Wei Wang (W)

Department of Pharmacology and Toxicology and BIO5 Institute, University of Arizona, Tucson, Arizona 85721-0207, United States.
ORCID: 0000-0001-6043-0860

Qianqian Yin (Q)

Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, P. R. China.

Yongqiang Zhang (Y)

Shanghai Frontiers Science Center of Optogenetic Techniques for Cell Metabolism, Shanghai Key Laboratory of New Drug Design, and School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P. R. China.
ORCID: 0000-0002-7210-4787

Classifications MeSH